The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Sulfonylurea Induced β-Cell Apoptosis in Cultured Human Islets
Open accessAbstract
Loss of beta-cell mass and function raises a concern regarding the application of sulfonylureas for the treatment of type 2 diabetes because previous studies have shown that agents that cause closure of inwardly rectifying K(+) sulfonylurea receptor subtype of ATP-sensitive potassium channels, such as tolbutamide and glibenclamide, induce apoptosis in beta-cell lines and rodent islets. Therefore, we investigated the effect of the new insulin secretagogues, repaglinide and nateglinide, and the sulfonylurea, glibenclamide, on beta-cell apoptosis in human islets. Human islets from six organ donors were cultured onto extracellular matrix-coated plates and exposed to glibenclamide, repaglinide, or nateglinide. The doses of the three compounds were chosen according to detected maximal effects, i.e. efficacy. Exposure of human islets for 4 h to 0.1 and 10 microm glibenclamide induced a 2.09- and 2.46-fold increase in beta-cell apoptosis, respectively, whereas repaglinide (0.01 and 1 microm) did not change the number of apoptotic beta-cells. At low concentration (10 microm), nateglinide did not induce beta-cell apoptosis. However, at high concentration of 1000 microm, it induced a 1.49-fold increase in the number of apoptotic beta-cells. Prolonged exposure for 4 d of the islets to the secretagogues induced beta-cell apoptosis. The increase was of 3.71- and 4.4-fold at 0.1 and 10 microm glibenclamide, 2.37- and 3.8-fold at 0.01 and 1 microm repaglinide, and of 3.2- and 4.6-fold at 10 and 1000 microm nateglinide, respectively. Glibenclamide at 0.1-10 nm (doses that were less efficient on insulin secretion) did not induce beta-cell apoptosis after 4 h incubation as well as 0.1 nm after 4 d incubation. However, 1 and 10 nm glibenclamide for 4 d induced a 2.24- and 2.53-fold increase in beta-cell apoptosis, respectively. Taken together, closure of the inwardly rectifying K(+) sulfonylurea receptor subtype of ATP-sensitive potassium channels induces beta-cell apoptosis in human islets and may precipitate the decrease in beta-cell mass observed in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Automated Method for Isolation of Human Pancreatic Islets
Ricordi, C., Lacy, P. E., Finke, E. H., Olack, B. J., & Scharp, D. W. (1988) · Diabetes · doi:10.2337/diab.37.4.413 · Cited by 1,310
Triggering and amplifying pathways of regulation of insulin secretion by glucose.
Henquin, J. C. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1751 · Cited by 1,201
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationSakuraba, H., Mizukami, H., Yagihashi, N., Wada, R., Hanyu, C., & Yagihashi, S. (2002) · Diabetologia · doi:10.1007/s125-002-8248-z · Cited by 681
Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes mellitus Revisited
Klöppel, G., Löhr, M., Habich, K., Oberholzer, M., & Heitz, P. U. (1985) · Pathology and Immunopathology Research · doi:10.1159/000156969 · Cited by 577
Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release.
Bonner-Weir, S., Trent, D. F., & Weir, G. C. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110910 · Cited by 467
Unger, R. H., & Grundy, S. (1985) · Diabetologia · doi:10.1007/bf00273856 · Cited by 452
Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications
Donath, M. Y., & Halban, P. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1336-4 · Cited by 430
Self-citationInflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes
Donath, M. Y., St�rling, J., Maedler, K., & Mandrup-Poulsen, T. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0450-y · Cited by 422
Self-citationDonath, M. Y., Gross, D. J., Cerasi, E., & Kaiser, N. (1999) · Diabetes · doi:10.2337/diabetes.48.4.738 · Cited by 405
Self-citationGlucose Induces β-Cell Apoptosis Via Upregulation of the Fas Receptor in Human Islets
Maedler, K., Spinas, G. A., Lehmann, R., Sergeev, P., Weber, M., Fontana, A., Kaiser, N., & Donath, M. Y. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1683 · Cited by 367
Self-citationGlucose and Tolbutamide Induce Apoptosis in Pancreatic β-Cells
Efanova, I. B., Zaitsev, S. V., Zhivotovsky, B., Köhler, M., Efendić, S., Orrenius, S., & Berggren, P.-O. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33501 · Cited by 364
High Glucose Causes Apoptosis in Cultured Human Pancreatic Islets of Langerhans
Federici, M., Hribal, M., Perego, L., Ranalli, M., Caradonna, Z., Perego, C., Usellini, L., Nano, R., Bonini, P., Bertuzzi, F., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1290 · Cited by 333
Islet growth and development in the adult
Bonner-Weir, S. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0240297 · Cited by 331
Eizirik, D. L., Korbutt, G. S., & Hellerström, C. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115989 · Cited by 311
Fuhlendorff, J., Rorsman, P., Kofod, H., Brand, C. L., Rolin, B., MacKay, P., Shymko, R., & Carr, R. D. (1998) · Diabetes · doi:10.2337/diabetes.47.3.345 · Cited by 310
Self-citationImproved Human Islet Isolation Using a New Enzyme Blend, Liberase
Linetsky, E., Bottino, R., Lehmann, R., Alejandro, R., Inverardi, L., & Ricordi, C. (1997) · Diabetes · doi:10.2337/diab.46.7.1120 · Cited by 310
Leahy, J. L., Cooper, H. E., Deal, D. A., & Weir, G. C. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112389 · Cited by 292
Insulin Resistance or Insulin Deficiency: Which Is the Primary Cause of NIDDM?
Taylor, S. I., Accili, D., & Imai, Y. (1994) · Diabetes · doi:10.2337/diab.43.6.735 · Cited by 289
Islet Secretion in a New Experimental Model for Non-insulin-dependent Diabetes
Weir, G. C., Clore, E. T., Zmachinski, C. J., & Bonner-Weir, S. (1981) · Diabetes · doi:10.2337/diab.30.7.590 · Cited by 248
Alvarsson, M., Sundkvist, G., Lager, I., Henricsson, M., Berntorp, K., Fernqvist-Forbes, E., Steen, L., Westermark, G., Westermark, P., Örn, T., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2231 · Cited by 170
Marshak, S., Leibowitz, G., Bertuzzi, F., Socci, C., Kaiser, N., Gross, D. J., Cerasi, E., & Melloul, D. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1230 · Cited by 167
Oberholzer, J., Triponez, F. D. R., Mage, R., Andereggen, É., hler, L. B., tin, N. C., Fournier, B., Goumaz, C., Lou, J., Philippé, J., et al. (2000) · Transplantation · doi:10.1097/00007890-200003270-00016 · Cited by 156
Maedler, K., Fontana, A., Ris, F., Sergeev, P., Toso, C., Oberholzer, J., Lehmann, R., Bachmann, F., Tasinato, A., Spinas, G. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122686299 · Cited by 140
Self-citationLing, Z., Kiekens, R., Mahler, T., Schuit, F. C., Pipeleers-Marichal, M. A., Sener, A., Klöppel, G., Malaisse, W. J., & PIPELEERS, D. G. (1996) · Diabetes · doi:10.2337/diab.45.12.1774 · Cited by 106
Schumacher, S., Abbasi, I., Weise, D., Hatorp, V., Sattler, K., Sieber, J., & Hasslacher, C. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100280 · Cited by 96
Type II Diabetes, Glucose “Non-Sense,” and Islet Desensitization
Robertson, R. P. (1989) · Diabetes · doi:10.2337/diab.38.12.1501 · Cited by 89
Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible?
Cerasi, E. (1995) · Diabetologia · doi:10.1007/bf00400591 · Cited by 88
Hansen, A. M. K., Christensen, I. T., Hansen, J. B., Carr, R. D., Ashcroft, F. M., & Wahl, P. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2789 · Cited by 88
Self-citationMealtime Glucose Regulation With Nateglinide in Healthy Volunteers
Kalbag, J., Walter, Y. H., Nedelman, J. R., & McLeod, J. F. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.73 · Cited by 77
Kaiser, N., CORCOS, A. P., Sarel, I., & Cerasi, E. (1991) · Endocrinology · doi:10.1210/endo-129-4-2067 · Cited by 76
The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents
Rosak, C. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00207-0 · Cited by 69
Glucose-induced [Ca2+]i abnormalities in human pancreatic islets: important role of overstimulation.
Björklund, A., Lansner, A., & Grill, V. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1840 · Cited by 69
Insulin Resistance Is Not Necessarily an Essential Component of Type 2 Diabetes
Gerich, J. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6646 · Cited by 68
Sustained Enhancement of Ca2+ Influx by Glibenclamide Induces Apoptosis in RINm5F Cells
Iwakura, T., Fujimoto, S., Kagimoto, S., Inada, A., Kubota, A., Someya, Y., Ihara, Y., Yamada, Y., & Seino, Y. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2616 · Cited by 58
Chachin, M., Yamada, M., Fujita, A., Matsuoka, T., Matsushita, K., & Kurachi, Y. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044917 · Cited by 49
Jaber, L. A., Antal, E. J., Slaughter, R. L., & Welshman, I. R. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1300 · Cited by 29
Gromada, J., Bokvist, K. B., Høy, M., Olsen, H., Lindström, P., Hansen, B., Gotfredsen, C., Rorsman, P., & Thomsen, M. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470133 · Cited by 9
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Yusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446
Mechanisms of β-Cell Death in Type 2 Diabetes
Donath, M. Y., Ehses, J. A., Maedler, K., Schumann, D. M., Ellingsgaard, H., Eppler, E., & Reinecke, M. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s108 · Cited by 444
Self-citation
Metadata
- Authors
- Maedler, K., Carr, R. D., Bosco, D., Zuellig, R. A., Berney, T., & Donath, M. Y.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-01
- Volume
- 90
- Issue
- 1
- Pages
- 501-506
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1982293047
- Cited by
- 333
- References
- 43
- FWCI
- 19.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.